



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gosselin *et al.*

Serial No.: 10/022,276

Group Art Unit: 1623

Filed: December 14, 2001

Examiner: L. Eric Crane

For: β -L-2'-Deoxy-Nucleosides for the Treatment of Hepatitis BAssistant Commissioner for Patents
Washington, DC 20231

July 17, 2002

Amendment and Response to Office Action

Sir:

In response to the Office Action mailed on April 11, 2002, please amend the application as follows.

In the Specification

Please amend the paragraph on page 1, beginning on line 3, with the following rewritten paragraph:

B ¹ This application is a continuation application of U.S. patent application number 09/371,747 filed on August 8, 1999, now U.S. Patent No. 6,395,716, which claims priority to U.S. provisional application number 60/096,110, filed on August 10, 1998 and U.S. provisional application number 60/131,352, filed on April 28, 1999. [~]

B ² Please add the following paragraph as a new paragraph at the end of page 9.

B ² ^N The term EC₅₀ refers to the concentration of nucleoside necessary to inhibit the replication of virus by 50%. ^N

#6/B
7-20-02
RECEIVED
JUL 29 2002
ENTER 1600/2900

57

B